Recent Research Analysts’ Ratings Changes for Kura Oncology (KURA)

Several analysts have recently updated their ratings and price targets for Kura Oncology (NASDAQ: KURA):

• 3/7/2025 – Kura Oncology was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 3/6/2025 – Kura Oncology had its price target lowered by analysts at UBS Group AG from $27.00 to $14.00. They now have a “buy” rating on the stock.
• 3/4/2025 – Kura Oncology was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating.
• 2/27/2025 – Kura Oncology had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $36.00 price target on the stock.
• 2/27/2025 – Kura Oncology was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 2/27/2025 – Kura Oncology had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
• 2/6/2025 – Kura Oncology had its price target raised by analysts at Wedbush from $34.00 to $36.00. They now have an “outperform” rating on the stock.
• 2/6/2025 – Kura Oncology was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating.
• 2/6/2025 – Kura Oncology had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $28.00 price target on the stock.
• 2/6/2025 – Kura Oncology had its price target raised by analysts at HC Wainwright from $37.00 to $40.00. They now have a “buy” rating on the stock.

Kura Oncology Trading Down 2.2 %

Shares of KURA stock opened at $7.53 on Monday. Kura Oncology, Inc. has a 12-month low of $6.98 and a 12-month high of $24.17. The company has a market capitalization of $608.09 million, a PE ratio of -3.19 and a beta of 0.85. The firm has a 50 day moving average price of $8.00 and a two-hundred day moving average price of $13.29. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. As a group, analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Insider Activity

In other news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Kura Oncology by 7.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company’s stock worth $1,147,000 after purchasing an additional 9,050 shares during the period. Woodline Partners LP grew its stake in Kura Oncology by 20.6% during the fourth quarter. Woodline Partners LP now owns 172,704 shares of the company’s stock worth $1,504,000 after buying an additional 29,497 shares in the last quarter. Velan Capital Investment Management LP bought a new position in Kura Oncology in the 4th quarter valued at about $1,306,000. Squarepoint Ops LLC acquired a new position in shares of Kura Oncology in the 4th quarter valued at approximately $799,000. Finally, Two Sigma Advisers LP raised its position in shares of Kura Oncology by 147.1% in the 4th quarter. Two Sigma Advisers LP now owns 242,200 shares of the company’s stock valued at $2,110,000 after buying an additional 144,201 shares in the last quarter.

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.